Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.44 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000873 | 1.00 | HTR2C (0.52) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL464281 | 1.00 | HTR2C (0.52) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL15122671 | 0.90 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL15122669 | 0.90 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL31107806 | 0.90 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL5083077 | 0.87 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL5083074 | 0.87 | HTR2C (0.51) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL4301411 | 0.86 | HTR2C (0.50) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL14814214 | 0.84 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9AGLA | |
| SCHEMBL6691930 | 0.84 | HTR2C (0.48) | HTR2CSMN1; SMN2NPC1RAB9AGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2018-09-11 | — | — | US | claimed |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | Indiana University Research and Technology Corpora tion (US) | 2016-06-23 | — | — | US | claimed |
| US-9217012-B2 | Inhibitors of protein tyrosine phosphatases | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2015-12-22 | — | — | US | claimed |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) | 2012-04-12 | — | — | US | claimed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | claimed |
| EP-3985001-B1 | PHARMACEUTICAL COMPOSITION FOR USE IN TREATING A CANCER | SERVIER LAB (FR) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731219-A2 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | Promega Corporation (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | KUMQUAT BIOSCIENCES INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | ARTIOS PHARMA LIMITED (GB) | 2025-07-15 | — | — | US | disclosed |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | PROMEGA CORPORATION | 2025-01-02 | — | — | US | disclosed |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2011-03-17 | — | — | US | disclosed |
| WO-2010118241-A2 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| EP-2142512-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119825-A2 | IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2008-10-09 | — | — | WO | disclosed |
| WO-2005014540-A1 | CYCLIC AMINE BASE-1 INHIBITORS HAVING A HETEROCYCLIC SUBSTITUENT | SCHERING CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| US-4508727-A | Antihypertensive 2-oxo-imidazolidine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 1985-04-02 | — | — | US | disclosed |
| EP-0095163-A2 | 2-Oxo-imidazolidine compounds, a process for preparing the same and a pharmaceutical composition | Tanabe Seiyaku Co., Ltd. (JP) | 1983-11-30 | — | — | EP | disclosed |
| US-4045556-A | ANTIDEPRESSANTS, PYSCHOSTIMULANTS; SILYLATION | SCHWERTNER EBERHARD | 1977-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072043-B2 | Inhibitors of protein tyrosine phosphatases | PTPRCAP, PTPRF, PTPRS | HTR2C 3132/4885SMN1; SMN2 4271/4885NPC1 3543/4885 |
| US-12551555-B2 | Compositions and methods for potentiating immune activity | PTPRCAP, PTPN2, PTPRC | HTR2C 3283/4885SMN1; SMN2 2223/4885NPC1 2688/4885 |
| US-20250066368-A1 | DNA POLYMERASE THETA INHIBITOR AND USE THEREOF | POLQ, POLB, POLM | HTR2C 4394/4885SMN1; SMN2 2924/4885NPC1 3569/4885 |
| US-20160176922-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | HTR2C 3132/4885SMN1; SMN2 4271/4885NPC1 3543/4885 |
| US-20250003974-A1 | COMPOUNDS AND METHODS OF USE THEREOF FOR ASSESSING TARGET ENGAGEMENT FOR DNA POLYMERASE THETA | POLQ, POLB, POLM | HTR2C 2875/4885SMN1; SMN2 3851/4885NPC1 3173/4885 |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | TTR, TYR, ABL1 | HTR2C 304/4885SMN1; SMN2 22/4885NPC1 2914/4885 |
| US-20120088720-A1 | INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES | PTPRCAP, PTPRF, PTPRS | HTR2C 3132/4885SMN1; SMN2 4271/4885NPC1 3543/4885 |
| US-20110065691-A1 | THERAPEUTIC PIPERAZINES | PDE4A, PDE4B, PDE4D | HTR2C 680/4885SMN1; SMN2 923/4885NPC1 1880/4885 |
| US-12358886-B2 | Heterocyclic compounds for use in the treatment of cancer | SDHA, DPYD, TP53 | HTR2C 1893/4885SMN1; SMN2 2897/4885NPC1 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.